PNTG
The Pennant Group, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
39.09
▲ 0.09 (0.23%)
MARKET · —
Price
Open
39.00
Prev close
39.00
Day high
39.25
Day low
38.66
Volume
275.15K
Market cap
$1.36B
P/E (TTM)
42.73
52W range
22.26 – 42.69
Trailing performance
Returnvs SPY
1W
-1.12%
+0.2%
1M
-2.34%
-6.1%
3M
+12.40%
+9.3%
6M
+20.30%
+9.2%
YTD
+38.12%
+25.8%
1Y
+54.53%
+34.5%
3Y
+224.00%
+149.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.36B
Enterprise value$1.88B
Revenue (TTM)$1.10B
Gross profit$215.83M
EBITDA$74.57M
Net income$32.32M
EPS (TTM)$0.91
Free cash flow$2.74M
Total cash$15.27M
Total debt$495.55M
Book value / share$10.24
Shares outstanding34.93M
Float33.21M
Short % of float2.01%
Dividend yield—
Beta (5Y)1.29
Valuation & profitability ratios
Trailing P/E42.73
Forward P/E24.50
PEG ratio2.24
Price / sales—
Price / book3.80
EV / revenue1.71
EV / EBITDA25.26
Gross margin19.59%
Operating margin6.19%
Profit margin2.93%
Return on equity10.42%
Return on assets4.50%
Debt / equity122.53
Current ratio1.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $947.71M | $695.24M | $544.89M | $473.24M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $29.58M | $22.56M | $13.38M | $6.64M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $29.58M | $22.56M | $13.38M | $6.64M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.33 | 0.36 | +9.1% |
| Mar 2026 | 0.31 | 0.32 | +4.9% |
| Dec 2025 | 0.32 | 0.34 | +7.7% |
| Sep 2025 | 0.29 | 0.30 | +4.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.35 | 7 | $299.47M | +30.8% |
| Next quarter | 0.37 | 7 | $303.86M | +5.0% |
| Current year | 1.40 | 7 | $1.18B | +24.9% |
| Next year | 1.59 | 7 | $1.28B | +7.8% |
Analyst targets & ownership
Mean target$46.67
High target$49.00
Low target$44.00
Implied upside19.38%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders5.05%
Held by institutions96.42%
Institutions holding302
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+121.49K
Net buying
Buy transactions
25
139.39K shares
Sell transactions
6
17.90K shares
Net transactions
+31
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 6, 26 | GUERISOLI BRENT Chief Executive Officer |
SELL | 4.29K | $165.07K | Direct |
| Aug 6, 26 | STEIK JASON PAUL Officer |
SELL | 1.39K | $53.70K | Direct |
| Aug 6, 26 | CHENEY KIRK S. General Counsel |
SELL | 1.39K | $53.66K | Direct |
| Jul 15, 26 | MORRIS GREGORY K. SR. Director |
STOCK | 1.90K | $0 | Direct |
| Jul 15, 26 | SMITH BARRY M Director |
STOCK | 1.90K | $0 | Direct |
| Jul 15, 26 | LAMB SCOTT E Director |
STOCK | 2.40K | $0 | Direct |
| Jul 15, 26 | CHRISTENSEN CHRISTOPHER R Director |
STOCK | 1.90K | $0 | Direct |
| Jul 15, 26 | SNAPPER SUZANNE D. Director |
STOCK | 1.90K | $0 | Direct |
| Jul 15, 26 | NACKEL JOHN G Director |
STOCK | 1.90K | $0 | Direct |
| Jul 15, 26 | COVEY STEPHEN M.R. Director |
STOCK | 1.90K | $0 | Direct |
| Jul 10, 26 | GUERISOLI BRENT Chief Executive Officer |
SELL | 3.16K | $131.30K | Direct |
| Jul 10, 26 | GUERISOLI BRENT Chief Executive Officer |
CONVERSION | 6.25K | $28.37K | Direct |
| Jul 7, 26 | GUERISOLI BRENT Chief Executive Officer |
SELL | 3.17K | $128.21K | Direct |
| Jul 7, 26 | GUERISOLI BRENT Chief Executive Officer |
CONVERSION | 6.25K | $28.37K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHRISTENSEN CHRISTOPHER R |
Director | 769.34K | Stock Award(Grant) |
COVEY STEPHEN M.R. |
Director | 44.05K | Stock Award(Grant) |
GOCHNOUR JOHN J |
Chief Operating Officer | 152.81K | Stock Award(Grant) |
GUERISOLI BRENT |
Chief Executive Officer | 99.54K | Sale |
LAMB SCOTT E |
Director | 58.94K | Stock Award(Grant) |
MORRIS GREGORY K. SR. |
Director | 37.30K | Stock Award(Grant) |
NACKEL JOHN G |
Director | 177.26K | Stock Award(Grant) |
SMITH BARRY M |
Director | 102.50K | Stock Award(Grant) |
SNAPPER SUZANNE D. |
Director | 230.36K | Stock Award(Grant) |
STRINGFIELD JOANNE |
Director | 30.27K | Sale |
Moving averages & technicals
SMA 10
38.98
+0.30% from price
SMA 20
39.57
-1.73% from price
SMA 50
38.45
+1.12% from price
SMA 100
35.30
+10.74% from price
SMA 200
32.47
+19.76% from price
EMA 12
39.16
-0.17% from price
EMA 26
39.16
-0.19% from price
EMA 50
38.23
+2.25% from price
RSI (14)
47.8
Neutral
MACD (12,26,9)
-0.01
Hist -0.16
ATR (14)
1.32
3.40% of price
Realised vol 30D
28.1%
Annualised
Bollinger upper
41.68
20, 2σ
Bollinger lower
37.45
20, 2σ
50 / 200 cross
Golden
38.45 vs 32.47
Trend bias
Above 200
+19.76%
Risk profile
Beta vs SPY
0.37
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
28.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.4%
Peak to trough
Max drawdown 5Y
-72.6%
Peak to trough
ATR 14
1.32
3.40% of price
Beta (reported)
1.29
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.75
Call-heavy session
Put / call open interest
0.46
Positioning, not flow
Max pain
35.00
-10.0% from spot
ATM implied vol
71.9%
Nearest strike to spot
Skew (10% OTM)
+16.9%
Puts bid over calls
Call volume
4
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
35.00
5 contracts
Heaviest put OI
35.00
5 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
RBC Raises Price Target on Pennant Group to $44 From $42, Keeps Outperform Rating
MT Newswires · 2d ago
Amid Legal Risks, This Company Is Still Rated a Buy
MarketBeat · 3d ago
3 Profitable Stocks We’re Skeptical Of
StockStory · 5d ago
3 Russell 2000 Stocks We Find Risky
StockStory · 12d ago
What Pennant Group (PNTG)'s Q2 Beat, Guidance Hike and New Acquisition Means For Shareholders
Simply Wall St. · 15d ago
OPCH vs. PNTG: Which Stock Is the Better Value Option?
Zacks · 15d ago
The Pennant Group Q2 Earnings Call Highlights
MarketBeat · 15d ago
Pennant Group Inc (PNTG) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised ...
GuruFocus.com · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.